Physicochemical and Biological Examination of Two Glatiramer Acetate Products
Herein we compared 40 mg/mL lots of the active ingredient, glatiramer acetate, manufactured by Mylan/Natco to the active ingredient, glatiramer acetate in Copaxone (Teva Pharmaceuticals, Ltd., Netanya Israel) using physicochemical (PCC) methods and biological assays. No differences were seen between...
Main Authors: | Arthur Komlosh, Vera Weinstein, Pippa Loupe, Tal Hasson, Bracha Timan, Attila Konya, Jessica Alexander, Sigal Melamed-Gal, Steffen Nock |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-07-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/7/3/49 |
Similar Items
-
Inconsistent Effects of Glatiramer Acetate Treatment in the 5xFAD Mouse Model of Alzheimer’s Disease
by: Berke Karaahmet, et al.
Published: (2023-06-01) -
Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers
by: Oliver Neuhaus, et al.
Published: (2021-03-01) -
Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01) -
Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01) -
Glatiramer acetate 40 mg/ml: A review of the results of GALA and GLACIER clinical studies
by: N. Yu. Lashch, et al.
Published: (2016-07-01)